technetium 99mTc fanolesomab (Neutrospec)
Jump to navigation
Jump to search
Introduction
Tradename: Neutrospec 2005: Marketing suspended for evaluation of immediate & life-threatening hypersensitivity reactions.[3]
Indications
- radiopharmaceutical used in scintigraphy
Adverse effects
- cardiopulmonary failure (hypersensitivity reaction)
- hypoxia, dyspnea, hypotension, cardiac arrest
- generally occurs within 30 minutes of administration
Mechanism of action
Notes
Manufacturer: Palatin
More general terms
References
- ↑ Prescriber's Letter 12(2): 2005 New Drugs Approved by the FDA in 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210216&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ FDA MedWatch http://www.fda.gov/medwatch/safety/2005/safety05.htm#NeutroSpec
- ↑ 3.0 3.1 Prescriber's Letter 13(2): 2006 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220215&pb=PRL (subscription needed) http://www.prescribersletter.com